跳转至内容

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

关于应对近期政策变化的重要更新,请点击此处查看详情。

Merck
CN

Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Clinical cancer research : an official journal of the American Association for Cancer Research (2015-04-22)
Xiangqian Guo, Vickie Y Jo, Anne M Mills, Shirley X Zhu, Cheng-Han Lee, Inigo Espinosa, Marisa R Nucci, Sushama Varma, Erna Forgó, Trevor Hastie, Sharon Anderson, Kristen Ganjoo, Andrew H Beck, Robert B West, Christopher D Fletcher, Matt van de Rijn
摘要

Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation. Little is known about its molecular heterogeneity and no targeted therapy currently exists for leiomyosarcoma. Recognition of different molecular subtypes is necessary to evaluate novel therapeutic options. In a previous study on 51 leiomyosarcomas, we identified three molecular subtypes in leiomyosarcoma. The current study was performed to determine whether the existence of these subtypes could be confirmed in independent cohorts. Ninety-nine cases of leiomyosarcoma were expression profiled with 3'end RNA-Sequencing (3SEQ). Consensus clustering was conducted to determine the optimal number of subtypes. We identified 3 leiomyosarcoma molecular subtypes and confirmed this finding by analyzing publically available data on 82 leiomyosarcoma from The Cancer Genome Atlas (TCGA). We identified two new formalin-fixed, paraffin-embedded tissue-compatible diagnostic immunohistochemical markers; LMOD1 for subtype I leiomyosarcoma and ARL4C for subtype II leiomyosarcoma. A leiomyosarcoma tissue microarray with known clinical outcome was used to show that subtype I leiomyosarcoma is associated with good outcome in extrauterine leiomyosarcoma while subtype II leiomyosarcoma is associated with poor prognosis in both uterine and extrauterine leiomyosarcoma. The leiomyosarcoma subtypes showed significant differences in expression levels for genes for which novel targeted therapies are being developed, suggesting that leiomyosarcoma subtypes may respond differentially to these targeted therapies. We confirm the existence of 3 molecular subtypes in leiomyosarcoma using two independent datasets and show that the different molecular subtypes are associated with distinct clinical outcomes. The findings offer an opportunity for treating leiomyosarcoma in a subtype-specific targeted approach.

材料
货号
品牌
产品描述

Sigma-Aldrich
Anti-LMOD1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab1
登录查看公司和协议定价
货号包装规格是否有货价格数量
50 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥377.06
100 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥502.48
500 mg
国内现货,预计发货时间 2025年4月21日
详情...
新价格,新优惠!
¥1,280.50
1 g
国内现货,预计发货时间 2025年4月21日
详情...
¥2,443.96
5 g
国内现货,预计发货时间 2025年4月21日
详情...
¥11,270.37
Sigma-Aldrich
Anti-ARL4C antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
登录查看公司和协议定价
货号包装规格是否有货价格数量
50 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥377.06
100 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥502.48
500 mg
国内现货,预计发货时间 2025年4月21日
详情...
新价格,新优惠!
¥1,280.50
1 g
国内现货,预计发货时间 2025年4月21日
详情...
¥2,443.96
5 g
国内现货,预计发货时间 2025年4月21日
详情...
¥11,270.37